• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels.

作者信息

Vuorio Alpo, Kovanen Petri T, Raal Frederick

机构信息

Mehiläinen Airport Health Centre, Vantaa, Finland.

Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.

出版信息

Ann Transl Med. 2025 Apr 30;13(2):11. doi: 10.21037/atm-25-40. Epub 2025 Apr 29.

DOI:10.21037/atm-25-40
PMID:40438517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12106114/
Abstract
摘要

相似文献

1
Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels.每日口服小分子脂蛋白(a)抑制剂muvalaplin在脂蛋白(a)水平升高的高危心血管疾病患者中取得了有前景的结果。
Ann Transl Med. 2025 Apr 30;13(2):11. doi: 10.21037/atm-25-40. Epub 2025 Apr 29.
2
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.Muvalaplin，一种口服小分子脂蛋白(a)形成抑制剂：一项随机临床试验。
JAMA. 2023 Sep 19;330(11):1042-1053. doi: 10.1001/jama.2023.16503.
3
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?脂蛋白(a)与动脉粥样硬化性心血管疾病：我们处于何种立场？
Int J Mol Sci. 2024 Mar 21;25(6):3537. doi: 10.3390/ijms25063537.
4
Oral agents for lowering lipoprotein(a).用于降低脂蛋白(a)的口服药物。
Curr Opin Lipidol. 2024 Dec 1;35(6):275-280. doi: 10.1097/MOL.0000000000000953. Epub 2024 Sep 25.
5
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.脂蛋白(a)与低密度脂蛋白胆固醇介导的心血管风险的独立性：一项基于参与者水平的荟萃分析。
Circulation. 2025 Jan 28;151(4):312-321. doi: 10.1161/CIRCULATIONAHA.124.069556. Epub 2024 Nov 4.
6
Elevated Plasma Lipoprotein(a) Level and Atherosclerotic Cardiovascular Disease Risks: A Large Clinical Retrospective Study.血浆脂蛋白(a)水平升高与动脉粥样硬化性心血管疾病风险：一项大型临床回顾性研究
Angiology. 2024 Mar 13:33197241239688. doi: 10.1177/00033197241239688.
7
In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.在儿科家族性高胆固醇血症中，脂蛋白(a)比 LDL-C 更能预测家族成员心血管疾病的早发。
J Clin Lipidol. 2018 Nov-Dec;12(6):1445-1451. doi: 10.1016/j.jacl.2018.07.014. Epub 2018 Jul 31.
8
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.口服穆瓦拉普林降低脂蛋白(a)：一项随机临床试验。
JAMA. 2025 Jan 21;333(3):222-231. doi: 10.1001/jama.2024.24017.
9
New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.降低低密度脂蛋白胆固醇以预防心血管疾病的新策略
Curr Cardiovasc Risk Rep. 2022 Sep;16(9):69-78. doi: 10.1007/s12170-022-00694-y. Epub 2022 Jun 25.
10
Does Adopting Western Low-density Lipoprotein Cholesterol Targets Expose Indians to a Higher Risk of Cardiovascular Events? Expert Opinion From the Lipid Association of India.采用西方低密度脂蛋白胆固醇目标是否会使印度人面临更高的心血管事件风险？来自印度脂质协会的专家意见。
J Assoc Physicians India. 2024 Oct;72(10):71-76. doi: 10.59556/japi.72.0692.

本文引用的文献

1
Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease.脂蛋白(a)作为心血管疾病的一个因果风险因素。
Curr Cardiovasc Risk Rep. 2025;19(1):8. doi: 10.1007/s12170-025-00760-1. Epub 2025 Feb 18.
2
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial.奥帕西然、氧化磷脂与全身炎症生物标志物：OCEAN(a)-DOSE试验结果
JAMA Cardiol. 2025 May 1;10(5):482-486. doi: 10.1001/jamacardio.2024.5433.
3
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects.
脂蛋白(a)作为一种药理学靶点：前提、前景与展望。
Circulation. 2025 Feb 11;151(6):400-415. doi: 10.1161/CIRCULATIONAHA.124.069210. Epub 2025 Feb 10.
4
Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study.美国临床动脉粥样硬化性心血管疾病人群中的脂蛋白(a)水平：Lp(a)HERITAGE研究的亚分析
J Clin Lipidol. 2025 Jan-Feb;19(1):28-38. doi: 10.1016/j.jacl.2024.11.007. Epub 2024 Dec 4.
5
Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin.使用新型异构体不敏感免疫测定法测量脂蛋白(a)颗粒说明了莫瓦拉普林的疗效。
J Lipid Res. 2025 Jan;66(1):100723. doi: 10.1016/j.jlr.2024.100723. Epub 2024 Dec 6.
6
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.口服穆瓦拉普林降低脂蛋白(a)：一项随机临床试验。
JAMA. 2025 Jan 21;333(3):222-231. doi: 10.1001/jama.2024.24017.
7
The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.德国脂蛋白吸附治疗登记处-第十一次年度报告摘要。
Atherosclerosis. 2024 Nov;398:118601. doi: 10.1016/j.atherosclerosis.2024.118601. Epub 2024 Sep 19.
8
Extension of Heterozygous Familial Hypercholesterolemia Treatment Recommendations by Including Both Low-density Lipoprotein and Lipoprotein(a) Burden - a Unique Opportunity to Improve Patient Prognosis.通过纳入低密度脂蛋白和脂蛋白(a)负担来扩展杂合子家族性高胆固醇血症的治疗建议——改善患者预后的独特机会。
Eur J Prev Cardiol. 2024 Sep 20. doi: 10.1093/eurjpc/zwae304.
9
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.炎症、胆固醇、脂蛋白(a)与女性30年心血管结局
N Engl J Med. 2024 Dec 5;391(22):2087-2097. doi: 10.1056/NEJMoa2405182. Epub 2024 Aug 31.
10
Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease.极低脂蛋白(a)水平与新发糖尿病和非酒精性肝病风险的关联。
Atheroscler Plus. 2024 Jul 11;57:19-25. doi: 10.1016/j.athplu.2024.07.001. eCollection 2024 Sep.